Asciminib is indicated for:
Population group: both men and women, only adults (18 years old or older)
Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Asciminib is contraindicated in the following cases: